Drugs
2
in active trials · 4 in all
Trials
3 active
6 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 2 | — | |||
| Also tested for | Solid Tumor, Non Small Cell Lung Cancer and 5 more | ||||
| Open drug page | |||||
In vivo BCMA CAR-T |
Phase 1 | 31 Aug 2027Phase 1 trial completes | |||
| How it works | Reprograms the patient's own immune T cells | ||||
| Next date | 31 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | ||||
| Open drug page | |||||
About
- No active trial
- MV-NIS, VSV-IFNβ-NIS and avelumab
- SEC filings
- None: Vyriad is private
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev